Publication: Elabela deficiency promotes preeclampsia and cardiovascular malformations in mice
dc.contributor.coauthor | Ho, Lena | |
dc.contributor.coauthor | van Dijk, Marie | |
dc.contributor.coauthor | Chye, Sam Tan Jian | |
dc.contributor.coauthor | Messerschmidt, Daniel M. | |
dc.contributor.coauthor | Chng, Serene C. | |
dc.contributor.coauthor | Ong, Sheena | |
dc.contributor.coauthor | Yi, Ling Ka | |
dc.contributor.coauthor | Boussata, Souad | |
dc.contributor.coauthor | Goh, Grace Hui-Yi | |
dc.contributor.coauthor | Afink, Gijs B. | |
dc.contributor.coauthor | Lim, Chin Yan | |
dc.contributor.coauthor | Dunn, N. Ray | |
dc.contributor.coauthor | Solter, Davor | |
dc.contributor.coauthor | Knowles, Barbara B. | |
dc.contributor.department | N/A | |
dc.contributor.kuauthor | Reversade, Bruno | |
dc.contributor.kuprofile | Faculty Member | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.contributor.yokid | 274182 | |
dc.date.accessioned | 2024-11-10T00:05:10Z | |
dc.date.issued | 2017 | |
dc.description.abstract | Preeclampsia (PE) is a gestational hypertensive syndrome affecting between 5 and 8% of all pregnancies. Although PE is the leading cause of fetal and maternal morbidity and mortality, its molecular etiology is still unclear. Here, we show that ELABELA (ELA), an endogenous ligand of the apelin receptor (APLNR, or APJ), is a circulating hormone secreted by the placenta. Elabela but not Apelin knockout pregnant mice exhibit PE-like symptoms, including proteinuria and elevated blood pressure due to defective placental angiogenesis. In mice, infusion of exogenous ELA normalizes hypertension, proteinuria, and birth weight. ELA, which is abundant in human placentas, increases the invasiveness of trophoblast-like cells, suggesting that it enhances placental development to prevent PE. The ELA-APLNR signaling axis may offer a new paradigm for the treatment of common pregnancy-related complications, including PE. | |
dc.description.indexedby | WoS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 6352 | |
dc.description.openaccess | NO | |
dc.description.publisherscope | International | |
dc.description.sponsorship | A*STAR Joint Council Organization | |
dc.description.sponsorship | Strategic Positioning Fund on Genetic Orphan Diseases from the Biomedical Research Council, A*STAR, Singapore | |
dc.description.sponsorship | Ferring Research Institute Innovation Grant | |
dc.description.sponsorship | A*STAR Investigatorship, an EMBO We thank T. Quertermous (Stanford University, USA) for sharing the Apln and Apj knockout mice | |
dc.description.sponsorship | T. Veenboer (AMC, Netherlands) for assistance with human placenta samples | |
dc.description.sponsorship | D. Kalicharan for technical assistance with electron microscopy | |
dc.description.sponsorship | members of the Advanced Molecular Pathology Laboratory, Institute of Molecular and Cell Biology, for assistance with histopathology | |
dc.description.sponsorship | the Institute of Medical Biology Microscopy Unit for assistance with imaging | |
dc.description.sponsorship | and the Genome Institute of Singapore sequencing facility for assistance with RNA-seq. RNA-seq data are deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive under accession number PRJNA391361. The data reported in this manuscript are tabulated in the main paper and in the supplementary materials. The authors acknowledge financial support from the A*STAR Joint Council Organization (Young Researcher Collaborative Grant) and a Strategic Positioning Fund on Genetic Orphan Diseases from the Biomedical Research Council, A*STAR, Singapore. M.v.D. and S.B. are supported by a Ferring Research Institute Innovation Grant. B.R. is a fellow of the Branco Weiss Foundation, a recipient of the A*STAR Investigatorship, an EMBO Young Investigator, and an AAA fellow from AMC/VUmc. The authors declare no competing financial interests. B.R. and L.H. are inventors on patent application 10201605841S submitted by A*STAR, Singapore, which covers the use of ELABELA for the diagnosis and treatment of preeclampsia. The ELABELA-deficient mice and custom antibody are available from B.R. under a material transfer agreement with A*STAR, Singapore. | |
dc.description.volume | 357 | |
dc.identifier.doi | 10.1126/science.aam6607 | |
dc.identifier.eissn | 1095-9203 | |
dc.identifier.issn | 0036-8075 | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-85021804387 | |
dc.identifier.uri | http://dx.doi.org/10.1126/science.aam6607 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/16388 | |
dc.identifier.wos | 407793600040 | |
dc.keywords | Growth factor | |
dc.keywords | Expression | |
dc.keywords | Receptor | |
dc.keywords | Tissue | |
dc.keywords | Cells | |
dc.keywords | APJ | |
dc.language | English | |
dc.publisher | American Association for the Advancement of Science (AAAS) | |
dc.source | Science | |
dc.subject | Science | |
dc.title | Elabela deficiency promotes preeclampsia and cardiovascular malformations in mice | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.authorid | 0000-0002-4070-7997 | |
local.contributor.kuauthor | Reversade, Bruno |